GRAL today
$121.35-$4.29 (-3.41%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minBearish
5 minConsolidating
Daily trend turns down below $41.50
Key levels
Resistance$161.90
Support$117.00
Support$92.50
Latest news & SEC filings
NewsGrail in talks with insurers over its Galleri screening test, executive says
ProductGRAIL official says wider use anticipated for Galleri screening test after FDA filing
ProductGrail executive sees FDA ruling on Galleri screening test by early 2027
AnalystPiper Sandler keeps Neutral rating on GRAIL, lifts price target to $130
All GRAL news →About GRAIL
GRAIL develops blood-based tests for finding cancer at an early stage. Its main offering, Galleri, checks a single blood sample for signals from many cancer types and indicates which organ or tissue may be affected. Customers include health systems, employers, insurers, and digital health companies, with operations centered on the United States and the United Kingdom.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
GRAIL, Inc. (GRAL)
What Is the Price Target for GRAL?
SEPT Low Target
$56.00
SEPT Mid Target
$118.00
SEPT High Target
$180.00
Analyst Consensus
$118.00
Is GRAL a Buy or Sell Right Now?
Thesis
- •Revenue growing 17.2% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for GRAL.
Start Free Trial →Is GRAL Overvalued or Undervalued?
Valuation Verdict
FAIR
Methods Used
P/B, Analyst Consensus
Fair Value
$126.39
27
Moat Score
NONE
5/9
Piotroski Score
3.5
Altman Z-Score
What Is Smart Money Doing with GRAL?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| SUMME GREGORY L | director | Buy | 237 | $32K | Oct 15, 2026 |
| CHASE WILLIAM J | director | Buy | 153 | $21K | Oct 15, 2026 |
| MIZELL STEVEN | director | Buy | 148 | $20K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 400 | $53K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 1,000 | $134K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 3,400 | $461K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 7,052 | $965K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 6,034 | $830K | Oct 15, 2026 |
| Ofman Joshua J. | director officer | Sale | 2,114 | $293K | Oct 15, 2026 |
| Partridge Andrew John | officer | Sale | 7,873 | $1.2M | Oct 5, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →GRAL Growth Story
Revenue YoY
17.2%
3yr Revenue CAGR
38.4%
EPS Growth YoY
82.51%
FCF Growth YoY
48.5%
Revenue Trend
STRONG
Dark Pool Trades for GRAL
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for GRAL, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 17:44:45 | $121.75 | 1,400 | $$170K | BUY |
| 17:38:54 | $121.10 | 11,200 | $$1.4M | SELL |
| 15:47:44 | $118.16 | 1,000 | $$118K | SELL |
| 14:51:08 | $117.82 | 2,000 | $$236K | BUY |
| 14:47:19 | $116.00 | 1,400 | $$162K | SELL |
5 dark pool trades shown · $$2.0M preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for GRAL
PREVIEWSEPT Investing provides real-time options flow tracking for GRAL, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $165 | Nov 20 | 8 | $$15 | 1 | SWEEP |
| PUT | $130 | Dec 18 | 36 | $$1757 | 1 | SWEEP |
| PUT | $130 | Nov 20 | 8 | $$1593 | 1 | SWEEP |
| PUT | $110 | Jan 21 | 435 | $$1164.0K | 400 | BLOCK |
4 options trades shown · 25% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for GRAIL, Inc. (GRAL) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →GRAL — frequently asked questions
What is GRAL stock price today?
GRAIL, Inc. (GRAL) is at $121.35, down 3.41% (-$4.29) at the Nov 12, 2026 close.
Why is GRAL stock moving today?
Latest GRAL news — Nov 10, 2026: Grail in talks with insurers over its Galleri screening test, executive says · Nov 10, 2026: GRAIL official says wider use anticipated for Galleri screening test after FDA filing
What is the GRAL price target?
The average analyst price target for GRAL is $118.00, ranging from $56 to $180, based on 11 analysts. Latest: TD Cowen maintains on Oct 13, 2026.
What do analysts rate GRAL?
Analyst ratings for GRAL: 1 Buy, 16 Hold, 0 Sell — consensus Hold.
Did GRAL beat earnings?
GRAL last reported on Aug 5, 2026: EPS -$2.56 vs -$2.66 expected — a beat of 3.8%.
Does GRAL pay a dividend?
GRAL does not currently pay a dividend.
What are GRAL support and resistance levels?
Support: $117.00, $92.50, $75.09. Resistance: $161.90.
What are insiders doing with GRAL?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on GRAL?
Nov 10, 2026: Grail in talks with insurers over its Galleri screening test, executive says · Nov 10, 2026: GRAIL official says wider use anticipated for Galleri screening test after FDA filing · Nov 10, 2026: Grail executive sees FDA ruling on Galleri screening test by early 2027